The RECOVERY trial of PIMS-TS: important lessons from the pandemic
- PMID: 38272047
- DOI: 10.1016/S2352-4642(23)00341-3
The RECOVERY trial of PIMS-TS: important lessons from the pandemic
Conflict of interest statement
MBFS declares grants from the US Centers for Disease Control and Prevention (CDC) and royalties from UpToDate for being an author on the section for MIS-C. AGR declares grants from the US National Institutes of Health (NIH) and US CDC to her institution; is the section editor of paediatric critical care medicine of UpToDate; honoraria for Grand Rounds presentation from St. Jude; honoraria from ThermoFisher; travel support from the International Sepsis Forum, Institut Merieux, and ThermoFisher; participation on data safety monitoring boards of the NIH Grace Study, REMAP-CAP, and NIH PREVENT-VILI; is on the medical advisory board of Families Fighting Flu; chairs the International Sepsis Forum; and has received reagents from Illumina.
Comment on
-
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.Lancet Child Adolesc Health. 2024 Mar;8(3):190-200. doi: 10.1016/S2352-4642(23)00316-4. Epub 2024 Jan 22. Lancet Child Adolesc Health. 2024. PMID: 38272046 Clinical Trial.
References
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
